vimpat

Latuda
neupro
Name VIMPAT® (Lacosamide)
Description VIMPAT® is an antiepileptic drug (functionalized amino acid). The antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels.
Indication

VIMPAT® (Lacosamide) is approved as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.

Strengths

VIMPAT® (Lacosamide) film coated tablets (50, 100, 150 and 200 mg), syrup 200ml bottles (10 mg/ml) and IV solution for infusion (10 mg/ml).

Regulatory Status

EMA approved: Film-coated tablets and Solution for infusion in August 2008. Syrup 10 mg/ml in February 2012.

FDA approved: Film-coated tablets and Solution for infusion in October 2008. Oral Solution 10 mg/ml approved in April 2010.

VIMPAT® Tablets are registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon

VIMPAT® Solution for Infusion is registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon

VIMPAT® Syrup is registered in KSA, Kuwait, UAE, Qatar, Bahrain, Oman & Lebanon

Business Partner UCB

 

Latuda
neupro